Prof. Emine Meltem OCAK DEMİRCİ

Personal Information

Office Phone: +90 212 440 0000 Extension: 13486
Office Phone: +90 212 440 0000 Extension: 13499
Fax Phone: +90 212 440 0052
Email: melocak@istanbul.edu.tr
Web: http://aves.istanbul.edu.tr/4142/
Address: İstanbul Üniversitesi, Eczacılık Fakültesi, Farmasötik Teknoloji Anabilim Dalı, Teknofarma Binası, Giriş Katı

International Researcher IDs
ORCID: 0000-0001-9214-3938
Publons / Web Of Science ResearcherID: AAD-9161-2020
ScopusID: 35076284600
Yoksis Researcher ID: 168485

Education Information

Post Doctorate, Pittsburg State University, Moleküler Görüntüleme Departmanı, Radyoloji Anabilim Dalı, United States Of America 2012 - 2014
Doctorate, Istanbul University, Faculty Of Pharmacy , Farmasötik Teknoloji Anabilim Dalı, Turkey 2005 - 2010
Doctorate, Leopold Franzens Universitaet Innsbruck, Radyofarmasi Laboratuvarı, Nükleer Tıp Anabilim Dalı, Austria 2007 - 2009
Postgraduate, Istanbul University, Faculty Of Pharmacy , Farmasötik Teknoloji Anabilim Dalı, Turkey 2003 - 2005
Undergraduate, Istanbul University, Faculty Of Pharmacy , Turkey 1999 - 2003

Foreign Languages

English, B2 Upper Intermediate

Certificates, Courses and Trainings

Education Management and Planning, Iyi Klinik Uygulamalar ve Temel Klinik Arastırma Egitimi, İÜKAMM, 2015
Education Management and Planning, Modül 1: Egitimde Etkilesim ve Katılımın Güçlendirilmesi, İstanbul Üniversites,, 2015
Education Management and Planning, Iç Denetim, Istanbul Üniversitesi, Ilaç Arastırma ve Uygulama Merkezi, 2015
Health&Medicine, 2nd Certificate Course of International Society of Radiolabeled Blood Elements, ISORBE, 2011
Health&Medicine, The Translational Imaging Workshop by AMIE From Mouse to Man, Erasmus, 2011
Health&Medicine, Stability testing, MK Danışmanlık, 2010
Health&Medicine, Postgraduate European Radiopharmacy Course, Block II, EANM, 2008
Health&Medicine, Temel Radyofarmasi Kursu, Türkiye Atom Enerjisi Kurumu, 2007
Health&Medicine, Postgraduate European Radiopharmacy Course, Block I, EANM, 2006
Health&Medicine, Postgraduate Diploma Course in Radiopharmaceutical Chemistry/Radiopharmacy, Block III, EANM, 2006
Health&Medicine, Tıpsal Araştırma Yönetim Birimi ve Biyoistatiksel Değerlendirme Kursu, Cerrahpaşa Tıp Fakültesi,

2005
Health&Medicine, Deney Hayvanları Uygulama ve Etik Kursu, Cerrahpaşa Tıp Fakültesi, 2005
Health&Medicine, Teknisyen Eğitim Kursu, TSNM, 2004
Health&Medicine, European School of Nuclear Medicine Certifcate, 27 th Seminar, TSNM, 2004

Dissertations

Doctorate, Peptitlerin Ga-68 ve Lu-177 ile İşaretlenmesi Üzerine Çalışmalar, Istanbul University, Eczacılık Teknolojisi, Farmasötik Teknoloji Anabilim Dalı, 2010
Postgraduate, Mikropartiküllerin Radyonüklit ile İşaretlenmesi ve Optimizasyonu, Istanbul University, Eczacılık Teknolojisi, Farmasötik Teknoloji Anabilim Dalı, 2005

Research Areas

Medicine, Internal Medicine Sciences, Nuclear medicine, Pharmacology and Therapeutics, Pharmaceutics Technology, Pharmaceutical Technology, Radiopharmacy, Health Sciences

Academic Titles / Tasks

Assistant Professor, Istanbul University, Faculty of Pharmacy , Department of Pharmaceutical Technology, 2012 - 2016
Research Assistant PhD, Istanbul University, Faculty of Pharmacy , Department of Pharmaceutical Technology, 2010 - 2012
Research Assistant, Istanbul University, Faculty of Pharmacy , Department of Pharmaceutical Technology, 2003 - 2010

Academic and Administrative Experience

Courses

TEZLE İLGİLİ ARAŞTIRMA ÇALIŞMALARI II, Postgraduate, 2021 - 2022, 2020 - 2021, 2019 - 2020
ENDÜSTRİ ECZACILIĞI KURULU V, Undergraduate, 2021 - 2022
DOZAJ ŞEKİLLERİNİN RADYOAKTİK İŞARETLENMESİ, Doctorate, 2021 - 2022, 2020 - 2021, 2019 - 2020, 2017 - 2018, 2016 - 2017, 2015 - 2016, 2014 - 2015
BİTİRME PROJESİ II, Undergraduate, 2021 - 2022, 2020 - 2021, 2019 - 2020, 2018 - 2019, 2017 - 2018, 2016 - 2017, 2015 - 2016
BİTİRME PROJESİ I, Undergraduate, 2021 - 2022, 2020 - 2021, 2019 - 2020, 2018 - 2019, 2017 - 2018, 2016 - 2017, 2015 - 2016
PHARMACEUTICAL TECHNOLOGY I, Undergraduate, 2021 - 2022, 2020 - 2021
ENDUSTRİ ECZACILIĞI KURULU VI, Undergraduate, 2021 - 2022, 2020 - 2021
RADYOFARMASİ, Undergraduate, 2021 - 2022, 2020 - 2021, 2019 - 2020, 2018 - 2019, 2017 - 2018, 2016 - 2017, 2015 - 2016
SCIENTIFIC RESEARCH AND TECHNICAL LITERATURE SCANNING, Undergraduate, 2021 - 2022

Advising Theses

Ocak E. M., Düşük çözünürlük gösteren ilaçların çözünme hızlarının iyileştirilmesine yönelik çalışmalar, Postgraduate, R.ABDULLAYEV(Student), 2021

OCAK DEMİRCİ E. M., 68Ga-PSMA-11 Üretimine ve Radyokimyasal Saflık Analizine Tasarımla Kalite (QbD) Prensiplerine Göre Kalite Uygulaması, Postgraduate, H.Pehlivanoğlu(Student), 2019
Ocak E. M., İLACIN TADININ MASKELENMESİ AMACIYLA AĞIZDA DAĞILABİLİR TABLET (ODT) FORMÜLASYONLARININ GELİŞTİRİLMESİ, Postgraduate, Ç.Kazaz(Student), 2017

Jury Memberships

Doctorate, Doctorate, İstanbul Üniversitesi, May, 2022
PhD Thesis Monitoring Committee Member, PhD Thesis Monitoring Committee Member, İstanbul Üniversitesi, March, 2022
Doctorate, Doctorate, İstanbul Üniversitesi, November, 2021
Doctorate, Evrim Atılay Takmaz, İstanbul Üniversitesi, Sağlık Bilimleri Ensitiusu, July, 2019
Doctoral Examination, Bülent Sabancı, İstanbul Üniversitesi, Sağlık Bilimleri Ensitiusu, November, 2018
Post Graduate, Amal Mohammad, İstanbul Üniversitesi Sağlık Bilimleri Enstitüsü, July, 2018
Doctoral Examination, Yetkin Elitez, İstanbul Üniversitesi, Sağlık Bilimleri Ensitiusu, May, 2018

Published journal articles indexed by SCI, SSCI, and AHCI

I. **Application of response surface methodology and quality by design to [⁶⁸Ga]Ga-PSMA-11 preparation**
Pehlivanoglu H., Ocak M., ÇAĞLAR ANDAÇ S.
JOURNAL OF RADIOANALYTICAL AND NUCLEAR CHEMISTRY, vol.333, no.1, pp.43-51, 2024 (SCI-Expanded)

II. **Application of Response Surface Methodology and Quality by Design to [68Ga]Ga-PSMA-11 Preparation**
Pehlivanoğlu H., Ocak Demirci E. M., Çağlar Andaç S.
JOURNAL OF RADIOANALYTICAL AND NUCLEAR CHEMISTRY, vol.1, no.1, pp.1, 2023 (SCI-Expanded)

III. **Clinical Experience with [225Ac]Ac-PSMA Treatment in Patients with [177Lu]Lu-PSMA-Refractory Metastatic Castration-Resistant Prostate Cancer**
Alan-Selcuk N., Beydagi G., Demirci E., OCAK DEMİRCİ E. M., Celik S., Oven B. B., Toklu T., Karaaslan I., Akcay K., Sonmez O., et al.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine, vol.64, no.10, pp.1574-1580, 2023 (SCI-Expanded)

IV. **Prevalence, comorbidities and mediators of childhood anxiety disorders in urban Turkey: a national representative epidemiological study**
Mutluer T., GÖRKER I., AKDEMİR D., ÖZDEMİR D., Ozel O. O., Vural P., Tufan A., Karacetin G., ARMAN A., Fis N. P., et al.
Social Psychiatry and Psychiatric Epidemiology, vol.58, no.6, pp.919-929, 2023 (SCI-Expanded)

V. **Development and validation of a UV-Radio-HPLC method to assess chemical and radiochemical purity of [68Ga] Ga-PSMA-11**
Pehlivanoglu H., Ocak M., Caglar-Andac S.
APPLIED RADIATION AND ISOTOPES, vol.190, 2022 (SCI-Expanded)

VI. **Value of Personalized Radiation Absorbed Dose Calculation for Radioiodine Ablation Therapy**
Sahin O., Selcuk N. A., Yeyin N., Akyel R., Toklu T., Beytur M. F., Can G., Demirci E., Boz A., Yapar F., et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, vol.49, no.SUPPL 1, 2022 (SCI-Expanded)

VII. **Peptide-Receptor Radionuclide Therapy (PRRT) with 225Ac-DOTA-TATE: Initial Results and Contribution to Progression-Free Survival**
Beydagi G., Demirci E., Selcuk N. A., Ocak M., Toklu T., Akcay K., Caner B., KABASAKAL L.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, vol.49, no.SUPPL 1, 2022 (SCI-

Expanded)

VIII. **Clinical Outcomes and Contribution to Progression-Free Survival of Radionuclide Therapy with 225Ac-PSMA in Metastatic Castration-Resistant Prostate Cancer (mCDPK)**
Beydagi G., Selcuk N. A., Demirci E., Ocak M., Toklu T., Akcay K., Caner B., Kabasakal L.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, vol.49, no.SUPPL 1, 2022 (SCI-Expanded)

IX. **The Role of [Ga-68]Ga-DOTA-FAPI-04 PET/CT on Altering Stage in Patients with Non-FDG-avid Lesions**
Beydagi G., Selcuk N. A., Demirci E., Akcay K., Oven B., Celik S., Sen F., Sonmez O., Caner B., Toklu T., et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, vol.49, no.SUPPL 1, 2022 (SCI-Expanded)

X. **Contribution of PSMA PET/CT to Evaluation of Response to Systemic Therapies: Preliminary Results**
Beydagi G., Demirci E., Selcuk N. A., Akcay K., Ocak M., Toklu T., Caner B., KABASAKAL L.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, vol.49, no.SUPPL 1, 2022 (SCI-Expanded)

XI. **EANM guideline on quality risk management for radiopharmaceuticals**
Gillings N., Hjelstuen O., Behe M., Decristoforo C., Elsinga P. H., Ferrari V., Kiss O. C., Kolenc P., Koziorowski J., Laverman P., et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, vol.49, no.10, pp.3353-3364, 2022 (SCI-Expanded)

XII. **Ga-[68]DOTA-FAPI-04 PET/CT imaging in a case of a signet ring cell carcinoma of stomach**
Alan Selçuk N., Ergen S., Demirci E., Ocak M., Kabasakal L.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, vol.48, no.13, pp.4523-4524, 2021 (SCI-Expanded)

XIII. **Evaluation of F-18 DOPA PET/CT in the detection of recurrent or metastatic medullary thyroid carcinoma: comparison with GA-68 DOTA-TATE PET/CT**
Asa S., Sönmezoğlu K., Uslu-Besli L., Sahin O. E., Karayel E., Pehlivanoglu H., Sager S., Kabasakal L., Ocak M., Sayman H. B.
ANNALS OF NUCLEAR MEDICINE, vol.35, pp.900-915, 2021 (SCI-Expanded)

XIV. **The Role of (68)GA-PSMA PET/CT Scan In Patients with Prostate Adenocarcinoma who Underwent Radical Prostatectomy**
Gültekin M. H., Demirci E., Turegun F. A., Kabasakal L., Sahin O. E., Ocak M., Önal B., Erozenci A.
UROLOGY JOURNAL, vol.18, no.1, pp.58-65, 2021 (SCI-Expanded)

XV. **Post-therapy imaging of 225Ac-DOTATATE treatment in a patient with recurrent neuroendocrine tumor**
Ocak M., Toklu T., Demirci E., Selçuk N., Kabasakal L.
European Journal of Nuclear Medicine and Molecular Imaging, vol.47, no.11, pp.2711-2712, 2020 (SCI-Expanded)

XVI. **Interobserver and intraobserver agreement on prostate-specific membrane antigen PET/CT images according to the miTNM and PSMA-RADS criteria**
Demirci E., Akyel R., Caner B., Alan-Selçuk N., Güven-Meşe Ş., Ocak M., Kabasakal L.
Nuclear medicine communications, vol.41, no.8, pp.759-767, 2020 (SCI-Expanded)

XVII. **Performance of f-18 fluorocholine PET/CT for detection of hyperfunctioning parathyroid tissue in patients with elevated parathyroid hormone levels and negative or discrepant results in conventional imaging**
Uslu-Beşli L., Sonmezoglu K., Teksoz S., Akgun E., Karayel E., Pehlivanoglu H., Khosroshahi B. R., Ocak M., Kabasakal L., Sager S., et al.
Korean Journal of Radiology, vol.21, no.2, pp.236-247, 2020 (SCI-Expanded)

XVIII. **ESTIMATION OF THE ORGAN ABSORBED DOSES AND EFFECTIVE DOSE FROM Ga-68-PSMA-11 PET SCAN**
Demirci E. M., Toklu T., Yeyin N., Ocak M., Alan-Selcuk N., Araman A., Kabasakal L.
RADIATION PROTECTION DOSIMETRY, vol.182, no.4, pp.518-524, 2018 (SCI-Expanded)

XIX. **Lu-177-DOTATATE therapy in patients with neuroendocrine tumours including high-grade (WHO G3) neuroendocrine tumours: response to treatment and long-term survival update**
Demirci E., Kabasakal L., Toklu T., Ocak M., Şahin O. A., Alan-Selcuk N., Araman A.
NUCLEAR MEDICINE COMMUNICATIONS, vol.39, no.8, pp.789-796, 2018 (SCI-Expanded)

XX. **Cu-64-Labeled Phosphonate Cross-Bridged Chelator Conjugates of c(RGDyK) for PET/CT Imaging of Osteolytic Bone Metastases**
Ocak M., Beaino W., White A., Zeng D., CAI Z., ANDERSON C. J.
CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, vol.33, no.2, pp.74-83, 2018 (SCI-Expanded)

XXI. **Efficacy and Safety of 177Lu-PSMA-617 Treatment in Castration Resistant Prostate Cancer with Organ Metastasis**
Sahin O. E., Akgun E., Demirci E., Ocak M., Akgun A., Akovali B., Karayel E., Pehlivanoglu H., Kabasakal L.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, vol.44, 2017 (SCI-Expanded)

XXII. **Comparison of F-18 DOPA and Ga-68 DOTA TATE in detection of recurrences or metastasis of medullary thyroid cancer**
Asa S., Sonmezoglu K., Akgun E. K., Khosroshah S. R., Toksoz S., Pehlivanoglu H., Karayel E., Ocak M., Kabasakal L., Bukey Y.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, vol.44, 2017 (SCI-Expanded)

XXIII. **The accuracy of 68Ga-PSMA PET/CT in primary lymph node staging in high-risk prostate cancer**
Obek C., DOGANCA T., Demirci E., Ocak M., Kural A. R., YILDIRIM A., YUCETAS U., Demirdag C., Erdogan S. M., Kabasakal L.
European Journal of Nuclear Medicine and Molecular Imaging, vol.44, no.11, pp.1806-1812, 2017 (SCI-Expanded)

XXIV. **Comparison of F-18 Choline PET/CT with Tc-99m MIBI and USG for Detection of Parathyroid Adenomas in Patients with Elevated Parathyroid Hormone Levels: Preliminary Results**
Uslu-Beli L., Sonmezoglu K., Akgun E. K., Teksoz S., Karayel E., Pehlivanoglu H., Ocak M., Ozturk T., Sager S., Kabasakal L., et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, vol.44, 2017 (SCI-Expanded)

XXV. **Extracting more information from Ga-68-PSMA-11 PET/CT performed for primary staging of prostate cancer**
Sahin O., Akgun E. K., Demirci E., Ocak M., Aygun A., Pehlivanoglu H., Karayel E., Kural A., Kabasakal L.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, vol.44, 2017 (SCI-Expanded)

XXVI. **The role of PSMA PET/CT imaging in restaging of prostate cancer patients with low prostate-specific antigen levels**
Kabasakal L., Demirci E., Nematyazar J., Akyel R., Razavi B., Ocak M., Aygun A., Obek C., Kural A. R.
NUCLEAR MEDICINE COMMUNICATIONS, vol.38, no.2, pp.149-155, 2017 (SCI-Expanded)

XXVII. **Preclinical Evaluation of F-18-ML-10 to Determine Timing of Apoptotic Response to Chemotherapy in Solid Tumors**
Demirci E., Ahmed R., Ocak M., Latoche J., Radelet A., DeBlasio N., Mason N. S., Anderson C. J., Mountz J. M.
MOLECULAR IMAGING, vol.16, 2017 (SCI-Expanded)

XXVIII. **The role of 68Ga-DOTA-TATE PET/CT scanning in the evaluation of patients with multiple myeloma: preliminary results.**
Sonmezoglu K., Vatankulu B., Elverdi T., Akyel R., Erkan M. E., Halac M., Ocak M., Demirci E., Aydin Y.
Nuclear medicine communications, vol.38, no.1, pp.76-83, 2017 (SCI-Expanded)

XXIX. **Normal distribution pattern and physiological variants of Ga-68-PSMA-11 PET/CT imaging**
Demirci E., Sahin O. E., Ocak M., Akovali B., Nematyazar J., Kabasakal L.
NUCLEAR MEDICINE COMMUNICATIONS, vol.37, no.11, pp.1169-1179, 2016 (SCI-Expanded)

XXX. **Normal Distribution Pattern and Physiological Variants of Ga-68-PSMA PET/CT**
Demirci E., Sahin O. E., Ocak M., Akovali B., Kabasakal L.
JOURNAL OF NUCLEAR MEDICINE, vol.57, 2016 (SCI-Expanded)

XXXI. **Preparation and in-vivo evaluation of dimenhydrinate buccalmucoadhesive films with enhanced bioavailability**
Pekoz A., Erdal M. S., Okyar A., Ocak M., Tekeli F., Kaptan E., Sagirli O., Araman A.

Drug Development and Industrial Pharmacy, vol.42, no.6, pp.916-925, 2016 (SCI-Expanded)

XXXII. **Pre-therapeutic dosimetry of normal organs and tissues of Lu-177-PSMA-617 prostate-specific membrane antigen (PSMA) inhibitor in patients with castration-resistant prostate cancer**
Kabasakal L., AbuQbeitah M., Aygun A., Yeyin N., Ocak M., Demirci E., Toklu T.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, vol.42, no.13, pp.1976-1983, 2015 (SCI-Expanded)

XXXIII. **Evaluation of PSMA PET/CT imaging using a Ga-68-HBED-CC ligand in patients with prostate cancer and the value of early pelvic imaging**
Kabasakal L., Demirci E., Ocak M., Akyel R., Nematyazar J., Aygun A., Halac M., Talat Z., ARAMAN A.
NUCLEAR MEDICINE COMMUNICATIONS, vol.36, no.6, pp.582-587, 2015 (SCI-Expanded)

XXXIV. **Folate Receptor-Targeted Multimodality Imaging of Ovarian Cancer in a Novel Syngeneic Mouse Model**
Ocak M., GILLMAN A. G., Bresee J., Zhang L., VLAD A. M., Mueller C., SCHIBLI R., EDWARDS W. B., ANDERSON C. J., GACH H. M.
MOLECULAR PHARMACEUTICS, vol.12, no.2, pp.542-553, 2015 (SCI-Expanded)

XXXV. **Ga-68-PSMA PET/CT imaging of metastatic clear cell renal cell carcinoma**
Demirci E., Ocak M., Kabasakal L., Decristoforo C., Talat Z., Halac M., Kanmaz B.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, vol.41, no.7, pp.1461-1462, 2014 (SCI-Expanded)

XXXVI. **FDG and FDG-labelled leucocyte PET/CT in the imaging of prosthetic joint infection**
Aksoy S. Y., Asa S., Ozhan M., Ocak M., Sager M. S., Erkan M. E., Halac M., Kabasakal L., Sonmezoglu K., Kanmaz B.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, vol.41, no.3, pp.556-564, 2014 (SCI-Expanded)

XXXVII. **Clinical value of technetium-99m-labeled octreotide scintigraphy in local recurrent or metastatic medullary thyroid cancers: A comparison of lesions with 18F-FDG-PET and MIBI images**
Sager S., Kabasakal L., Ocak M., Maecke H., Uslu L., Halac M., Asa S., Sager G., Onsel C., Kanmaz B.
Nuclear Medicine Communications, vol.34, no.12, pp.1190-1195, 2013 (SCI-Expanded)

XXXVIII. **Evaluation and comparison of Ga-68 DOTA-TATE and Ga-68 DOTA-NOC PET/CT imaging in well-differentiated thyroid cancer**
Ocak M., Demirci E., Kabasakal L., Aygun A., Tutar R. O., Araman A., Kanmaz B.
NUCLEAR MEDICINE COMMUNICATIONS, vol.34, no.11, pp.1084-1089, 2013 (SCI-Expanded)

XXXIX. **Comparison of Ga-68 DOTA-TATE and Ga-68 DOTA-LAN PET/CT imaging in the same patient group with neuroendocrine tumours: preliminary results**
Demirci E., Ocak M., Kabasakal L., Araman A., Ozsoy Y., Kanmaz B.
NUCLEAR MEDICINE COMMUNICATIONS, vol.34, no.8, pp.727-732, 2013 (SCI-Expanded)

XL. **Design and Evaluation of Novel Radiolabelled VIP Derivatives for Tumour Targeting**
Rangger C., Helbok A., Ocak M., Radolf T., Andreae F., Virgolini I. I., Von Guggenberg E., Decristoforo C.
ANTICANCER RESEARCH, vol.33, no.4, pp.1537-1546, 2013 (SCI-Expanded)

XLI. **Appearance of intracranial meningioma in FDG and 68Ga-DOTATOC PET/CT.**
YILMAZ S., Ocak M., Asa S., Gülsen F., HALAC M., Kabasakal L.
Revista espanola de medicina nuclear e imagen molecular, vol.32, pp.60-1, 2013 (SCI-Expanded)

XLII. **The different distribution patterns of FDG and FDG-labelled WBC in inflammatory and infectious lesions**
Yilmaz S., Ocak M., Asa S., Aliyev A., Ozhan M., Halac M., Sager S., Kabasakal L., Sonmezoglu K.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, vol.39, no.10, pp.1660-1661, 2012 (SCI-Expanded)

XLIII. **Comparison of Ga-68-DOTATATE and Ga-68-DOTANOC PET/CT imaging in the same patient group with neuroendocrine tumours**
Kabasakal L., Demirci E., Ocak M., Decristoforo C., Araman A., Ozsoy Y., Uslu I., Kanmaz B.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, vol.39, no.8, pp.1271-1277, 2012 (SCI-Expanded)

XLIV. **Initial experience of biological stability and image timing of Ga-68 DOTANOC in somatostatin receptor (sstr) expressing organ and tumor**
Ocak M., Kabasakal L., Demirci E., Aygun A., Ozcan R., Kanmaz B.
JOURNAL OF NUCLEAR MEDICINE, vol.53, 2012 (SCI-Expanded)

XLV. **177Lu-[DOTA0, Tyr3] octreotate therapy in iodine refractory thyroid cancer: Comparison of dosimetry with therapy of thyroid cancer and neuroendocrine tumors**
Yeyin N., Toklu T., Demirci E., Kabasakal L., Aygun A., Ocak M., Selcuk N., Kanmaz B.
JOURNAL OF NUCLEAR MEDICINE, vol.53, 2012 (SCI-Expanded)

XLVI. **Diagnostic impact of 68Ga-DOTA-TATE PET/CT imaging in the detection of recurrent or metastatic medullary thyroid carcinoma and elevated calcitonin levels**
Aliyev A., Ocak M., Kabasakal L., Decristoforo C., Demirci E., Yilmaz S., Uslu I.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, vol.38, 2011 (SCI-Expanded)

XLVII. **Comparison of 68Ga-DOTA-TATE and 68Ga-DOTA-LAN PET/CT imaging in the same patient group with Neuroendocrine Tumors**
Demirci E., Ocak M., Kabasakal L., Decristoforo C., Uslu I.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, vol.38, 2011 (SCI-Expanded)

XLVIII. **99m Tc-HYNIC-TATE in detection of well differantiated thyroid cancer with negative radioiodine uptake**
Asa S., Ekmekcioglu O., Ocak M., Decristoforo C., Arslan E., Kabasakal L., Sager S., Araman A., Uslu U.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, vol.38, 2011 (SCI-Expanded)

XLIX. **The value of Tc-99m HYNIC-TATE SPECT/CT in patients with recurrent or metastatic Medullary Thyroid Carcinoma**
Asa S., Ekmekcioglu O., Ocak M., Decristoforo C., Arslan E., Kabasakal L., Sager S., Onsel C., Araman A., Uslu U.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, vol.38, 2011 (SCI-Expanded)

L. **177Lu-DOTA-TATE in Peptide Receptor Radionuclide Therapy: first year experience in Turkey**
Kabasakal L., Demirci E., Ocak M., Decristoforo C., Papilla C., Araman A., Uslu I.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, vol.38, 2011 (SCI-Expanded)

LI. **Early and Late 68Ga-DOTA-NOC PET/CT in somatostatin receptor (sstr) expressing organ and tumour**
Demirci E., Ocak M., Kabasakal L., Decristoforo C., Ozsoy Y., Araman A., Uslu I.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, vol.38, 2011 (SCI-Expanded)

LII. **Comparison of 68Ga-DOTA-TATE and 68Ga-DOTA-NOC PET/CT imaging in the same patient group with Neuroendocrine Tumors**
Demirci E., Ocak M., Kabasakal L., Decristoforo C., Gunes B., Arslan E., Araman A., Uslu I.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, vol.38, 2011 (SCI-Expanded)

LIII. **The Diagnostic Efficiency of Tc-99m-HYNIC-octreotate SPECT-CT in Comparison with In-111-pentetrotide in the Detection of Neuroendocrine Tumours**
Deveci E. K., Ocak M., Turker S., Kabasakal L., Ugur O.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, vol.38, 2011 (SCI-Expanded)

LIV. **68Ga-DOTA-TATE and 68Ga-DOTA-NOC PET in neuroendocrine tumors: First year experience in Turkey**
Demirci E., Ocak M., Kabasakal L., Gunes B., Decristoforo C., Uslu I.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, vol.38, 2011 (SCI-Expanded)

LV. **99mTc-EDDA/HYNIC-TATE scintigraphy: Results of 1 year experience in Turkey**
Asa S., Ekmekcioglu O., Ocak M., Decristoforo C., Kabasakal L., Sager S., Onsel C., Araman A., Uslu U.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, vol.38, 2011 (SCI-Expanded)

LVI. **Radio labelling of peptides for PET, SPECT and therapeutic applications using a fully automated disposable cassette system**
Petrik M., Knetsch P. A., Knopp R., Imperato G., Ocak M., von Guggenberg E., Haubner R., Silbernagl R., Decristoforo C.
NUCLEAR MEDICINE COMMUNICATIONS, vol.32, no.10, pp.887-895, 2011 (SCI-Expanded)

LVII. **Intraoperative Localization of Recurrent Medullary Carcinoma of the Thyroid Using Tc-99m HYNIC-TATE and a Surgical Gamma Probe**
Aliyev A., Ocak M., Kabasakal L., Haciyev Y., Ozhan M., Vural O., Ozturk O., Demirkaya A., Uslu I.
CLINICAL NUCLEAR MEDICINE, vol.36, no.9, pp.831-833, 2011 (SCI-Expanded)

LVIII. **Comparison of biological stability and metabolism of CCK2 receptor targeting peptides, a collaborative project under COST BM0607**
Ocak M., Helbok A., Rangger C., Peitl P. K., Nock B. A., Morelli G., Eek A., Sosabowski J. K., Breeman W. A. P., Reubi J. C., et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, vol.38, no.8, pp.1426-1435, 2011 (SCI-Expanded)

LIX. **Influence of biological assay conditions on stability assessment of radiometal-labelled peptides exemplified using a 177Lu-DOTA-minigastrin derivative**
Ocak M., Helbok A., von Guggenberg E., Ozsoy Y., Kabasakal L., Kremser L., Decristoforo C.
Nuclear Medicine and Biology, vol.38, no.2, pp.171-179, 2011 (SCI-Expanded)

LX. **Impurity in 68Ga-peptide preparation using processed generator eluate**
Petrik M., Ocak M., Rupprich M., Decristoforo C.
Journal of Nuclear Medicine, vol.51, no.3, pp.495, 2010 (SCI-Expanded)

LXI. **Full automation of Ga-68 labelling of DOTA-peptides including cation exchange prepurification**
Ocak M., Antretter M., Knopp R., Kunkel F., Petrik M., Bergisadi N., Decristoforo C.
APPLIED RADIATION AND ISOTOPES, vol.68, no.2, pp.297-302, 2010 (SCI-Expanded)

LXII. **Comparision of biological stability of Lu-177-DOTA-minigastrin derivatives and determination of enzymatic cleavage site**
Ocak M., Helbok A., von Guggenberg E., Ozsoy Y., Bergisadi N., Kabasakal L., Decristoforo C.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, vol.36, 2009 (SCI-Expanded)

LXIII. **Fully automated synthesis of radiolabelled peptides using a disposable cassette system**
Petrik M., Ocak M., Knopp R., von Guggenberg E., Haubner R., Decristoforo C.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, vol.36, 2009 (SCI-Expanded)

LXIV. **Cyclic minigastrin analogues for gastrin receptor scintigraphy with technetium-99m: Preclinical evaluation**
von Guggenberg E., Sallegger W., Helbok A., Ocak M., King R., Mather S. J., Decristoforo C.
Journal of Medicinal Chemistry, vol.52, no.15, pp.4786-4793, 2009 (SCI-Expanded)

LXV. **177Lu-DOTA-CYCLOGASTRIN: STABILITY ASSESSMENT AND EVALUATION IN VITRO**
Ocak M., Decristoforo C., Rangger C., Helbok A., Sallegger W., von Guggenberg E.
JOURNAL OF LABELLED COMPOUNDS & RADIOPHARMACEUTICALS, vol.52, 2009 (SCI-Expanded)

LXVI. **QUALITY CONTROL OF Ga-68, In-111, Y-90 AND Lu-177 LABELED DOTA-DERIVATISED PEPTIDE ANALOGS USING A COMBINATION OF HPLC AND TLC**
Ocak M., Decristoforo C., Bergisadi N., Kabasakal L., von Guggenberg E.
JOURNAL OF LABELLED COMPOUNDS & RADIOPHARMACEUTICALS, vol.52, 2009 (SCI-Expanded)

LXVII. **68Ga-LABELLING OF PEPTIDES USING DIFFERENT STRATEGIES FOR A DISPOSABLE CASSETTE SYSTEM**
Ocak M., Petrik M., Knopp R., von Guggenberg E., Bergisadi N., Decristoforo C.
JOURNAL OF LABELLED COMPOUNDS & RADIOPHARMACEUTICALS, vol.52, 2009 (SCI-Expanded)

LXVIII. **Somatostatin scintigraphy in patients with cushing's syndrome (preliminary data)**
Sager S., Kabasakal L., Ocak M., Halac M., Nisli C., Maecke H., Onsel C., Uslu I.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, vol.33, 2006 (SCI-Expanded)

LXIX. **Optimization of radiolabelling efficiency of [DOTA0, Tyr3] octreotate with 177Lu, 90Y, 111In**
Ocak M., Kabasakal L., Uslu E., Decristoforo C., Mut S., Uslu I.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, vol.33, 2006 (SCI-Expanded)

LXX. **Comparison of in-111 octreotide scintigraphy with tc-99m hynic-toc/tate scintigraphy in the same patient group for diagnosis of somatostatin receptor expressing tumors**
Sager S., Kabasakal L., Yimaz S., Ocak M., Sanli Y., Maecke H., Onsel C., Uslu I.

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, vol.33, 2006 (SCI-Expanded)

LXXI. **Comparison of TC-99m Hynic-Octreotide and TC-99m Hynic-Octreotate in the same Patient Group with Somatostatin Receptor Expressing Tumors**
Kabasakal L., Sager S., Ocak M., Maecke H., Nisli C., Onsel C., Uslu I.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, vol.32, 2005 (SCI-Expanded)

LXXII. **Clinical Value of TC-99M Hynic-Octreotide and TC-99M Hynic-Octreotate Scintigraphy in Patients with Somatostatin Expressing Tumours**
Sager S., Kabasakal L., Ocak M., Nisli C., Maecke H., Onsel C., Uslu I.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, vol.32, 2005 (SCI-Expanded)

LXXIII. **Clinical Experience with TC-99m Hynic-Toc and Hynic-Tate Octreotid Scintigraphy in the Follow-Up of Thyroid Cancers**
Sager S., Kabasakal L., Halac M., Kasikcioglu D., Ocak M., Maecke H., Nisli C., Sonmezoglu K., Onsel C., Uslu I.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, vol.32, 2005 (SCI-Expanded)

Articles Published in Other Journals

I. **Almost Complete Response with a Single Administration Ac-225-DOTATATE in a Patient with a Metastatic Neuroendocrine Tumor of Unknown Primary**
ALAN SELÇUK N., Demirci E., Ocak M., Toklu T., Ergen S., KABASAKAL L.
MOLECULAR IMAGING AND RADIONUCLIDE THERAPY, vol.31, no.2, pp.139-141, 2022 (ESCI)

II. **Guideline on current good radiopharmacy practice (cGRPP) for the small-scale preparation of radiopharmaceuticals**
Gillings N., Hjelstuen O., Ballinger J., Behe M., Decristoforo C., Elsinga P., Ferrari V., Peitl P. K., Koziorowski J., Laverman P., et al.
EJNMMI RADIOPHARMACY AND CHEMISTRY, vol.6, no.1, 2021 (ESCI)

III. **Recent Developments of Radiopharmaceuticals for Neuroendocrine Tumor Imaging and Therapy**
OCAK E. M.
NUCLEAR MEDICINE SEMINARS, vol.7, 2021 (Peer-Reviewed Journal)

IV. **Formulation development and evaluation of taste-masked atomoxetine hydrochloride orally disintegrating tablets (Odts)**
Kazaz Ç., Mesut B., Özsoy Y., Ocak E. M.
Journal of Research in Pharmacy, vol.25, no.5, pp.715-727, 2021 (ESCI)

V. **EANM guideline on the validation of analytical methods for radiopharmaceuticals.**
Gillings N., Todde S., Behe M., Decristoforo C., Elsinga P., Ferrari V., Hjelstuen O., Peitl P., Koziorowski J., Laverman P., et al.
EJNMMI radiopharmacy and chemistry, vol.5, pp.7, 2020 (ESCI)

VI. **Formulation design and taste assessment in orally disintegrating tablets Ağızda dağılan tabletlerde formülasyon tasarımı ve tat değerlendirilmesi**
KAZAZ Ç., Ocak M., MESUT B., Özsoy Y.
Fabad Journal of Pharmaceutical Sciences, vol.44, no.2, pp.169-178, 2019 (Scopus)

VII. **Guidance on validation and qualification of processes and operations involving radiopharmaceuticals**
Todde S., Kolenc Peitl P., Elsinga P., Koziorowski J., Ferrari V., OCAK M., Hjelstuen O., Patt M., Mindt T., Behe M.
EJNMMI Radiopharmacy and Chemistry, no.2, pp.1-29, 2017 (Scopus)

VIII. **Lu-177-PSMA-617 Prostate-Specific Membrane Antigen Inhibitor Therapy in Patients with Castration-Resistant Prostate Cancer: Stability, Bio-distribution and Dosimetry**
Kabasakal L., Toklu T., Yeyin N., Demirci E., Abuqbeitah M., Ocak M., Aygun A., Karayel E., Pehlivanoglu H., Selcuk N. A.
MOLECULAR IMAGING AND RADIONUCLIDE THERAPY, vol.26, no.2, pp.62-68, 2017 (ESCI)

IX. **PET Radyofarmasötikleri**

OCAK M.
Toraks Cerrahisi Bülteni, vol.6, no.2, pp.154-160, 2015 (Peer-Reviewed Journal)

X. **The Diagnostic Efficiency of 99mTc-EDDA/HYNIC-Octreotate SPECT-CT in Comparison with 111In-Pentetrotide in the Detection of Neuroendocrine Tumours.**
Koçyiğit Deveci E., Ocak M., Bozkurt M., Türker S., KABASAKAL L., Uğur Ö.
Mol Imaging Radionucl Ther, no.22, pp.76-84, 2013 (Peer-Reviewed Journal)

XI. **Gastroenteropankreatik Nöroendokrin Tümörlerde Peptid Reseptör Radyonüklit Tedavi ve Y-90 Mikroküre Tedavisi**
KABASAKAL L., Ocak .
Turkiye Klinikleri J Med Oncol-Special Topics, no.6, pp.38-45, 2013 (Peer-Reviewed Journal)

Books & Book Chapters

I. **Radiopharmaceuticals for Radionuclide Therapy**
Ocak E. M., Demirci E., R. Nedrow J., Krimins R.
in: Handbook of Nuclear Medicine and Molecular Imaging for Physicists, Michael Ljungberg, Editor, Taylor eBookstore , Florida, pp.39-53, 2022

II. **Karaciğerin Primer ve Sekonder Tümörlerinde Transarteriyel Radyoembolizasyon: Radyofarmasötikler**
OCAK .
in: Karaciğerin Primer ve Sekonder Tümörlerinde Löko-Rejyonel Tedavi Seçenekleri; Endikasyon, Tedavi ve Takip, Numan F., Editor, Türkiye Türkiye Klinikleri Yayınevi, Ankara, pp.75-79, 2020

III. **SPECT Radyofarmasötikleri İşaretleme Yöntemleri ve Radyasyon Korunması**
OCAK M.
in: Radyofarmasotiklerin Uretiminde ve Klinik Kullaniminda Radyasyon Korunmasi - 2019, Demir M., Editor, Türkiye Klinikleri Yayınevi, Ankara, pp.56-65, 2019

IV. **Radyonüklit Tedavide Kullanılan Radyofarmasötiklerin Temel Özellikleri ve Üretimi**
OCAK .
in: Radyonüklit Tedavi, Bekiş R., Polack B., Bozkurt MF, Editor, O'tıp Kitapevi Yayınları, İzmir, pp.1-20, 2019

V. **Teranostik Radyofarmasötikler ve Yeni Nesil Ajanlar**
OCAK M.
in: Nükleer Onkolojide Teranostik Uygulamalar, Prof.Dr.Zehra Özcan, Editor, Türkiye Klinikleri Yayınevi, Ankara, pp.5-10, 2018

VI. **Quality Control In the Production of Raiopharmaceuticals**
OCAK M.
in: Quality Control In the Production of Raiopharmaceuticals, IAEA-TECDOC-1856, Editor, International Atomic Energy Agency, Vienna, pp.1-150, 2018

VII. **PET Radyofarmasötikleri**
OCAK .
in: Uygulamalı Temel Radyofarmasi, Prof.Dr.Perihan Ünak, Prof.Dr.Gülay Durmuş Altun,Prof.Dr.Serap Teks., Editor, Nobel Tıp Kitabevleri, İstanbul, pp.159-177, 2017

VIII. **Radyofarmasötikler**
USLU İ., Ocak M.
in: Nükleer Tıp Ders Kitabı, Prof.Dr.Çetin Önsel, Editor, İstanbul Üniversitesi, İstanbul, pp.37-55, 2009

Refereed Congress / Symposium Publications in Proceedings

I. **Ac-225-DOTATATE ile Peptit-Reseptör Radyonüklit Tedavisi (PRRT): İlk Sonuçlar ve Progresyonsuz Sağkalıma Katkısı**

Beydağı G., Demirci E., Alan-Selçuk N., Ocak E. M., Toklu T., Akçay K., Caner B., Kabasakal L.
34. Ulusal Nükleer Tıp Kongresi, Antalya, Turkey, 27 - 31 March 2022, pp.17

II. **Metastatik Prostat Kanserinde Ac-225-PSMA ile Radyonüklit Tedavisinin Klinik Sonuçları ve Progresyonsuz Sağkalıma Katkısı**
Beydağı G., Alan Selçuk N., Demirci E., Akçay K., Ocak E. M., Toklu T., Kabasakal L., Caner B.
34. Ulusal Nükleer Tıp Kongresi, Antalya, Turkey, 27 - 31 March 2022, pp.14

III. **PSMA PET/BT'nin Sistematik Tedavilere Yanıt Değerlendirmeye Katkısı**
Beydağı G., Demirci E., Alan-Selçuk N., Akçay K., Ocak E. M., Toklu T., Caner B., Kabasakal L.
34. Ulusal Nükleer Tıp Kongresi, Antalya, Turkey, 27 - 31 March 2022, pp.21

IV. **BCS Sınıf II Olanzapin'in Çözünürlüğünün Kendiliğinden Nanoemülsifiye Olabilen Sistemlerle Arttırılması**
Abdulayeva R., Mesut B., Ocak E. M.
International Battalgazi Scientific Studies Congress-V, Malatya, Turkey, 18 - 20 December 2020, pp.1

V. **Tasarımla Kalite Yaklaşımı ile 68GA-PSMA-11 Radyofarmasötiğinin Hazırlanması**
Pehlivanoğlu H., Aygün A., Karayel E., Ocak E. M., Sönmezoğlu K., Çağlar Andaç S.
31.Ulusal Nükleer Tıp Kongresi ve 8.Balkan Nükleer Tıp Kongresi, Muğla, Turkey, 10 - 14 April 2019, pp.120

VI. **A PRELIMINARY STUDY FOR QUALITY BY DESIGN (QbD) IN SMALL-SCALEPREPARATION OF 68GA PSMA11**
Pehlivanoğlu H., Demirci E. M., Çağlar Andaç S.
1st International Symposium on Graduate Research in Science: Focus on Entrepreneurship and Innovation, İstanbul, Turkey, 4 - 06 October 2018, pp.212

VII. **ANALYTICAL QUALITY BY DESIGN IN RADIOCHEMICAL PURITY OF[68Ga]PSMA-11, A PRELIMINARY STUDY**
Pehlivanoğlu H., Ocak E. M., Çağlar Andaç S.
1 st International Symposium on Graduate Research in Science Focus on Entrepreneurship and Innovation (ISGRS 2018), İstanbul, Turkey, 4 - 06 October 2018, pp.213

VIII. **Comparison of F18 DOPA and Ga68 DOTA TATE in detection of recurrences or metastasis of medullary thyroid cancer**
Asa S., Sönmezoğlu K., Akgün E., Razavıkhosroshahı S., Teksöz S., Ocak E. M., Kabasakal L., Bükey Y.
European Association of Nuclear Medicine Congress 2017, Vienna, Austria, 21 - 25 October 2017, pp.1

IX. **THE ACCURACY OF 68GALLIUM-PSMA PET/CT IN PRIMARY LYMPH NODE STAGING FOR HIGH RISK PROSTATE CANCER**
Obek C., DOGANCA T., Demirci E., Ocak M., Kural A. R., YILDIRIM A., YUCETAS U., Demirdag C., Erdogan S. M., Kabasakal L.
Annual Meeting of the American-Urological-Association (AUA), Massachusetts, United States Of America, 12 - 16 May 2017, vol.197

X. **Electrochemistry of99mTc(III) DMSA and 99mTc(V) MDP Complexes Used for Medical Diagnostic and Radiotracers**
TUTAR R., TÜRKER ACAR E., ORTABOY S., OCAK DEMİRCİ E. M., SÖNMEZOĞLU K., KABASAKAL L., ATUN G.
2nd International Turkic World Conference on Chemical Sciences and Technologies, Üsküp, Macedonia, 26 - 30 October 2016, pp.67

XI. **18F-fluorocholine PET/CT imaging is useful in localization of hyper-functioning parathyroid tissue in primary hyperparathyroidism: a comparative study with 99mTc-MIBI SPECT/CT and neck ultrasonography**
Sonmezoglu K., Vatankulu B., Ocak M., Tutar R. O., Pehlivanoglu H., Karayel E., Karatas A., Teksoz S., Kabasakal L., Bukey Y.
Annual Congress of the European-Association-of-Nuclear-Medicine, Barcelona, Spain, 15 - 19 October 2016, vol.43

XII. **Preparation of 18F-Fluoromethylcholine in a fully automated radiochemical synthesizer: a tertiary university hospital experience**
Karayel E., Pehlivanoglu H., Aygun A., Tutar R., Kurt A., Ocak M., Kabasakal L., Sonmezoglu K.
Annual Congress of the European-Association-of-Nuclear-Medicine, Barcelona, Spain, 15 - 19 October 2016, vol.43

XIII. **Lu-177-DOTA-TATE therapy in patients with NETs: Response to treatment and long-term survival update**
Demirci E., Sahin O. E., Ocak M., Aygun A., Uslu I., Kabasakal L.
Annual Congress of the European-Association-of-Nuclear-Medicine (EANM), Barcelona, Spain, 15 - 19 October 2016, vol.43

XIV. **Peptide receptor radionuclide therapy in malignant pheochromocytoma and paraganglioma treatment**
Nematyazar J., Vatankulu B., Demirci E., Asa S., Ocak M., Uslu U., Kabasakal L.
Annual Congress of the European-Association-of-Nuclear-Medicine, Barcelona, Spain, 15 - 19 October 2016, vol.43

XV. **Preparation of (F-18)FDOPA in a fully automated radiochemical synthesizer: a tertiary university hospital experience**
Pehlivanoglu H., Karayel E., Aygun A., Tutar R., Kurt A., Ocak M., Kabasakal L., Sonmezoglu K.
Annual Congress of the European-Association-of-Nuclear-Medicine (EANM), Barcelona, Spain, 15 - 19 October 2016, vol.43

XVI. **Biodistribution patterns of Lu177-DKFZ-PSMA617 and Ga68-DKFZ-PSMA11 in the same patient group**
Yeyin N., Sahin O. E., Vatankulu B., Toklu T., Demirci E., Aygun A., Karayel E., Pehlivan H., Selcuk N. A., Ocak M., et al.
Annual Congress of the European-Association-of-Nuclear-Medicine, Barcelona, Spain, 15 - 19 October 2016, vol.43

XVII. **Normal Distribution Pattern and Physiological Variants of Ga-68-PSMA PET/CT**
Demirci E., Sahin O., Ocak M., Akovali B., Nematyazar J., Kabasakal L.
Annual Congress of the European-Association-of-Nuclear-Medicine, Barcelona, Spain, 15 - 19 October 2016, vol.43

XVIII. **68Ga-PSMA HBED-CC PET/CT imaging may be useful in detection of differentiated thyroid cancer: a comparative study with 68Ga-DOTA-TATE PET/CT and 18F-FDG PET/CT imaging**
Vatankulu B., Akgun E., Ocak M., Demirci E., Uslu L., Sager S., Halac M., Kabasakal L., Sonmezoglu K.
Annual Congress of the European-Association-of-Nuclear-Medicine (EANM), Barcelona, Spain, 15 - 19 October 2016, vol.43

XIX. **Effects of Lutetium-177 PSMA-i and Radioiodine Therapy on Salivary and Lacrimal Glands**
Sahin O. E., Vatankulu B., Akyel R., Nematyazar J., Demirci E., Pehlivan H., Karayel E., Aygun A., Ocak M., Kabasakal L.
Annual Congress of the European-Association-of-Nuclear-Medicine, Barcelona, Spain, 15 - 19 October 2016, vol.43

XX. **Cervical lymph node metastases is not an uncommon finding in Ga-68-DKFZ-PSMA-11 PET/CT imaging in patients with prostate cancer**
Nematyazar J., Şahin O. A., Razavi B., DEMIRCI E., Aygün A., Ocak M. T., Obek C., Kural A. R., Kabasakal L.
28th Annual Congress of the European-Association-of-Nuclear-Medicine (EANM), Hamburg, Germany, 10 - 14 October 2015, vol.42

XXI. **Pre-therapy Initial Dosimetry Results of Lu-177-DOTA-617-PSMA In Castration Resistant Prostate Cancer**
Abuqbeitah M. M., Yeyin N., Aygün A., Demirci E., Ocak M. T., Demir M., Kabasakal L.
28th Annual Congress of the European-Association-of-Nuclear-Medicine (EANM), Hamburg, Germany, 10 - 14 October 2015, vol.42

XXII. **Dosimetry Results of Lu-177-DKFZ-PSMA-617 Treatment in Castration Resistant Prostate Cancer Patients**
Yeyin N., Mohammad A., Kabasakal L., DEMIRCI E., Aygün A., Ocak M. T., Toklu T., Tanyildizi H., Selcuk N.
28th Annual Congress of the European-Association-of-Nuclear-Medicine (EANM), Hamburg, Germany, 10 - 14 October 2015, vol.42

XXIII. **Evaluation of in vivo and in vitro stability of Lu-177-DKFZ-617 for systemic radionuclide therapy in patients with castration resistant prostate cancer**
Ocak M. T., Aygün A., Yeyin N., DEMIRCI E., Karayel E., Araman A., Kabasakal L.
28th Annual Congress of the European-Association-of-Nuclear-Medicine (EANM), Hamburg, Germany, 10 - 14 October 2015, vol.42

XXIV. **Differences in biodistribution of Lu-177-DKFZ-PSMA-617 and Ga-68-DKFZ-PSMA-11 in the same patient group**

Şahin O. A., Nematyazar J., Razavi B., Yeyin N., Aygün A., Ocak M. T., DEMIRCI E., Kabasakal L.
28th Annual Congress of the European-Association-of-Nuclear-Medicine (EANM), Hamburg, Germany, 10 - 14 October 2015, vol.42

XXV. **Diagnostic value of (68)Ga - PSMA PET/CT in biochemical recurrence of prostate carcinoma with low PSA levels**
Demirci E., Nematyazar J., Akyel R., Razavi B., Aygün A., Ocak M. T., Halac M., Araman A., Kabasakal L.
28th Annual Congress of the European-Association-of-Nuclear-Medicine (EANM), Hamburg, Germany, 10 - 14 October 2015, vol.42

XXVI. **Ga-68-PSMA PET/CT imaging in patients with renal cell carcinoma: initial experience**
Nematyazar J., Razavi B., Akyel R., Demirci E., OCAK ., Aygün A., Halaç M., ARAMAN A. O., KABASAKAL L.
EANM'14, Göteborg, Sweden, 18 - 22 October 2014, pp.350

XXVII. **Evaluation of Ga-68-PSMA PET/CT imaging in patients with prostate cancer and comparison with bone scan**
Razavi B., Nematyazar J., Akyel R., Demirci E., OCAK M., Aygün A., Halaç M., ARAMAN A. O., KABASAKAL L.
EANM'14, Göteborg, Sweden, 18 - 22 October 2014, pp.3392

XXVIII. **Evaluation of Ga-68-PSMA PET/CT imaging in patients with prostate cancer and value of early pelvic imaging**
Akyel R., Demirci E., OCAK M., Nematyazar J., Aygün A., Halaç M., Talat Z., ARAMAN A. O., Kabasakal L.
EANM'14, Göteborg, Sweden, 18 - 22 October 2014, pp.235

XXIX. **177Lu-DOTA-TATE therapy in patients with NETs: Toxicity, response and prognostic indicators**
Demirci E., Ocak M., Kabasakal L., Aygun A., Araman A., Uslu I.
Annual Congress of the European-Association-of-Nuclear-Medicine (EANM), Gothenburg, Sweden, 18 - 22 October 2014, vol.41

XXX. **Multi-modal folate-targeted imaging of intraperitoneal ovarian tumors in mice**
Gillman A., Ocak ., Bresee J., Zhang L., Mueller C., Vlad A., Edwards B., Gach M., Anderson C.
Society of Nuclear Medicine and Molecular Imaging, St.Louis, United States Of America, 7 - 11 June 2014, vol.55, pp.500

XXXI. **Preclinical evaluation of the PET imaging radiotracer, F18-ML-10, for early detection of solid tumor response to chemotherapy**
Demirci E., Ahmed R., Ocak ., Anderson C., Mountz J.
Society of Nuclear Medicine and Molecular Imaging, St.Lois, United States Of America, 7 - 11 June 2014, vol.55, no.1, pp.1066

XXXII. **Evaluation of 64Cu- and 68Ga-NODAGA-c(RGDyK) in a rodent inflammatory paw model**
Ocak ., Demirci E., Day K., Latoche J., Liu J., Anderson C.
Society of Nuclear Medicine and Molecular Imaging, St.Louis, United States Of America, 7 - 11 June 2014, vol.55, pp.1222

XXXIII. **Transmucosal delivery of dimenhydrinate to rabbits employing mucoadhesive patch.**
YILDIZ PEKÖZ A., OKYAR A., OCAK DEMİRCİ E. M., KAPTAN E., TEKELİ F., ERDAL M. S., SAĞIRLI A. O.
9th World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology,, Lizbon, Portugal, 31 March - 03 April 2014, pp.269-270

XXXIV. **Evaluation of 68Ga-DOTA-TATE and 68Ga-DOTA-NOC PET/CT in Patients with Differentiated Thyroid Cancer**
Demirci E., KABASAKAL L., Ocak ., Aygün A., Halaç M., KANMAZ M. B.
25th Annual Congress of the European-Association-of-Nuclear-Medicine (EANM), Milan, Italy, 27 - 31 October 2013, pp.404

XXXV. **Comparison of positron emission tomography with 68Ga-DOTA-TATE and 18F FDG in neuroendocrine tumours**
Yilmaz s., Demirci E., Ocak M., Aygün A., Halaç M., Sager S., KABASAKAL L., KANMAZ M. B.
25th Annual Congress of the European-Association-of-Nuclear-Medicine (EANM), Milan, Italy, 27 - 31 October 2013, pp.588

XXXVI. **Imaging of Metastatic-Recurrent Paragangliomas and Pheochromocytomas with Ga-68 DOTATATE**

PET/CT

Demirci E., Ocak M., Yeyin N., Asa S., Aygün A., Halaç M., KABASAKAL L., KANMAZ M. B.

25th Annual Congress of the European-Association-of-Nuclear-Medicine (EANM), Milan, Italy, 27 - 31 October 2013, no.39, pp.517

XXXVII. **177Lu-[DOTA0,Tyr3] octreotate therapy in iodine refractory thyroid cancer: Comparison of dosimetry with therapy of thyroid cancer and neuroendocrine tumors**

Yeyin N., Demirci E., Toklu T., KABASAKAL L., Aygün A., Ocak M., Selçuk N., KANMAZ M. B.

25th Annual Congress of the European-Association-of-Nuclear-Medicine (EANM), Milan, Italy, 27 - 31 October 2013, pp.306

XXXVIII. **Comparison of I-123 MIBG Scintigraphy with Somatostatin Receptor Scintigraphy Using Tc-99m HYNIC TATE in Neuroblastoma Patients**

Uslu L., KABASAKAL L., Ocak ., Tuysuz G., Celkan T., Apak H., KANMAZ M. B.

25th Annual Congress of the European-Association-of-Nuclear-Medicine (EANM), Milan, Italy, 27 - 31 October 2013, pp.586

XXXIX. **Tc-99m mebrophenin hepatobiliary scintigraphy for assessment of lobar functional liver status by liver mebrophenin clearance rate in patients who will undergo Y-90-microsphere treatmen**

Kabasakal L., Yilmaz S., Tanyildizi H., Ocak M., Ozcan R., Aygun A., Atun G., Araman A., Kanmaz B.

Annual Congress of the European-Association-of-Nuclear-Medicine (EANM), Lyon, France, 19 - 23 October 2013, vol.40

XL. **Comparison of tumour and whole body absorbed doses of 177-Lu- DOTA-TATE and Lu-177 DOTA-NOC treatment in the same patient group**

Yeyin N., Kabasakal L., Akyel R., Ocak M., Toklu T., Selcuk N., Demir M., Kanmaz B.

Annual Congress of the European-Association-of-Nuclear-Medicine (EANM), Lyon, France, 19 - 23 October 2013, vol.40

XLI. **Relationship of tumor absorbed doses of 177Lu-DOTA-TATE treatment and uptake in pre-therapeutic Ga68 DOTA-TATE PET/CT imaging**

Demirci E., Kabasakal L., Yeyin N., Ocak M., Toklu T., Selcuk N., Kanmaz B.

Annual Congress of the European-Association-of-Nuclear-Medicine (EANM), Lyon, France, 19 - 23 October 2013, vol.40

XLII. **Biological Stabilization Studies of 68Ga DOTA-NOC Peptide via In Vitro Blood and Urine Samples By Using HPLC Analysis**

TUTAR R., KABASAKAL L., DEMİRCİ E., Aygün A., OCAK E. M., KANMAZ M. B.

IUPAC 44th World Chemistry Congress, İstanbul, Turkey, 11 - 16 August 2013, pp.797

XLIII. **A pharmaceutical radiochemical agent 99mtc-bromo-hida kit preparation and quality control via c-18 sep-pak cartridges and thin-layer chromatography for radioimaging**

Özcan Tutar R., Aygün A., Ocak M., Kabasakal L., ATUN G., Araman A., TUTAR R.

IUPAC 44th World Chemistry Congress, Turkey, 1 - 04 August 2013, pp.1302

XLIV. **Assessment of lobar functional liver status by liver mebrophenin clearance rate using Tc-99m mebrofenin hepatobiliary scintigraphy**

Yılmaz S., Ekmekçioğlu Ö., Tanyıldızı H., TUTAR R., OCAK E. M., Aygün A., KABASAKAL L., ATUN G., ARAMAN A. O., KANMAZ M. B.

SNMMI Annual Meeting, Vancouver, Bc, Canada, 8 - 12 June 2013, pp.590

XLV. **Evaluation of 64Cu-DBCO-CB-TE1K1P-c(RGDyK) and 64Cu-DBCO-CB-TE1A1P-c(RGDyK) for PET imaging of metastatic bone disease**

OCAK M., Beaino W., Zeng D., White A., Cai Z., Anderson C.

SNMMI 2013, Vancouver, Bc, Canada, 8 - 12 June 2013, vol.54, no.2, pp.1059

XLVI. **Hepatobiliyer Sistem Sintigrafisinde Tc-99m Mebrofenin Kullanılarak Farklı Klirens Hesaplama Metodlarının Karşılaştırılması**

Tanyıldızı H., KABASAKAL L., TUTAR R., Yılmaz S., Yeyin N., Aygün A., OCAK E. M., ÖKTEM Y., KANMAZ M. B.

25.Ulusal Nükleer Tıp Kongresi, Antalya, Turkey, 6 - 10 April 2013, pp.96-97

XLVII. **Tc-99m Mebrofenin hepatobiliyer sintigrafi yardımıyla mebrofenin klirens hızının hesaplanarak**

lobar karaciğer fonksiyonlarının değerlendirilmesi
Yılmaz Aksoy S., Tanyıldızı H., Ekmekçioğlu Ö., Özcan Tutar R., Ocak M., Aygün A., Kabasakal L., ATUN G., Araman A., Kanmaz B., et al.
25.Ulusal Nükleer Tıp Kongresi, Antalya, Turkey, 1 - 04 April 2013, pp.15

XLVIII. **Radyofarmasötik 99mTc-HIDA kiti hazırlanması ve kalite kontrol çalışmasının yapılması**
Aygün A., Özcan Tutar R., Ocak M., Kabasakal L., ATUN G., Araman A., Kanmaz B., TUTAR R.
25.Ulusal Nükleer Tıp Kongresi, Antalya, Turkey, 1 - 04 April 2013, pp.15

XLIX. **177Lu-[DOTA0,Tyr3] octreotate therapy in iodine refractory thyroid cancer: Comparison of dosimetry with therapy of thyroid cancer and neuroendocrine tumors**
Yeyin N., Demirci E., Toklu T., Kabasakal L., Aygun A., Ocak M., Selcuk N., Kanmaz B.
25th Annual Congress of the European-Association-of-Nuclear-Medicine (EANM), Milan, Italy, 27 - 31 October 2012, vol.39

L. **Comparison of I-123 MIBG Scintigraphy with Somatostatin Receptor Scintigraphy Using Tc-99m HYNIC TATE in Neuroblastoma Patients**
Uslu L., Kabasakal L., Ocak M., Tuysuz G., Celkan T., Apak H., Kanmaz B.
25th Annual Congress of the European-Association-of-Nuclear-Medicine (EANM), Milan, Italy, 27 - 31 October 2012, vol.39

LI. **Imaging of Metastatic-Recurrent Paragangliomas and Pheochromocytomas with Ga-68 DOTATATE PET/CT**
Demirci E., Ocak M., Yeyin N., Asa S., Aygun A., Halac M., Kabasakal L., Kanmaz B.
25th Annual Congress of the European-Association-of-Nuclear-Medicine (EANM), Milan, Italy, 27 - 31 October 2012, vol.39

LII. **Comparison of positron emission tomography with 68Ga-DOTA-TATE and 18F FDG in neuroendocrine tumours**
Yilmaz S., Demirci E., Ocak M., Aygun A., Halac M., Sager S., Kabasakal L., Kanmaz B.
25th Annual Congress of the European-Association-of-Nuclear-Medicine (EANM), Milan, Italy, 27 - 31 October 2012, vol.39

LIII. **Evaluation of 68Ga-DOTA-TATE and 68Ga-DOTA-NOC PET/CT in Patients with Differentiated Thyroid Cancer**
Demirci E., Kabasakal L., Ocak M., Aygun A., Halac M., Kanmaz B.
25th Annual Congress of the European-Association-of-Nuclear-Medicine (EANM), Milan, Italy, 27 - 31 October 2012, vol.39

LIV. **Lu-177 DOTA-TATE ile peptit reseptör radyonüklid tedavisinde absorbe doz değerleri**
Yeyin N., Toklu T., ÇAVDAR İ., Tanyıldızı H., Demirci E., OCAK DEMİRCİ E. M., aygün a., KABASAKAL L., DEMİR M.
24. Ulusal Nükleer Tıp Kongresi, Antalya, Turkey, 4 - 08 April 2012, pp.20

LV. **Initial Experience of Biological Stability and Image Timing of Ga-68 DOTANOC in Somatostatin Receptor (sstr) Expressing Organ and Tumor**
Demirci E., Kabasakal L., Ocak M., Aygun A., Ozcan R., Decristoforo C., Kanmaz B.
9th Annual European-Neuroendocrine-Tumor-Society (ENETS) Conference for the Diagnosis and Treatment of Neuroendocrine Tumor Disease, Copenhagen, Denmark, 7 - 09 March 2012, vol.96, pp.26

LVI. **Evaluation of 68Ga-DOTA-TATE and 68Ga-DOTA-LAN PET/CT in Somatostatin Exopressing Organs and Tumors**
Kabasakal L., Demirci E., Ocak M., Aygun A., Decristoforo C., Uslu I., Bedii K.
9th Annual European-Neuroendocrine-Tumor-Society (ENETS) Conference for the Diagnosis and Treatment of Neuroendocrine Tumor Disease, Copenhagen, Denmark, 7 - 09 March 2012, vol.96, pp.38

LVII. **Detection of somatostatin receptor-positive tumours using Tc-99m-EDDA/HYNIC-NOC and comparison with Tc-99m-EDDA/HYNIC-TATE in the same patient group**
Ocak M., Ekmekcioglu O., Kabasakal L., Decristoforo C., Asa S., Araman A., von Guggenberg E., Uslu I.
23rd Annual Congress of the European-Association-of-Nuclear-Medicine (EANM), Vienna, Austria, 9 - 13 October 2010, vol.37

LVIII. **Comparison of 99mTc-EDDA/HYNIC-TATE and 111 In Octreotide in the same patient group with**

somatostatin receptor expressing tumors
Ekmekcioglu O., Ocak M., Kabasakal L., Araman A., Decristoforo C., Nisli S., Uslu I.
23rd Annual Congress of the European-Association-of-Nuclear-Medicine (EANM), Vienna, Austria, 9 - 13 October 2010, vol.37

LIX. **Comparison and improvement of the metabolic stability of CCK-2 receptor targeting peptides, a collaborative project under COST BM0607**
Ocak M., Rangger C., Klingler M., Kabasakal L., Decristoforo C., von Guggenberg E.
23rd Annual Congress of the European-Association-of-Nuclear-Medicine (EANM), Vienna, Austria, 9 - 13 October 2010, vol.37

LX. **Comparison of (68)Ga-DOTA, Tyr(3), Thr(8) -octreotide PET/CT and (99m)Tc-HYNIC, Tyr(3), Thr(8)-octreotide SPECT/CT in neuroendocrine tumors**
Gunes B., Ocak M., Kabasakal L., Araman A., Decristoforo C., Ekmekcioglu O., Kaya R., Halac M., Uslu I.
23rd Annual Congress of the European-Association-of-Nuclear-Medicine (EANM), Vienna, Austria, 9 - 13 October 2010, vol.37

LXI. **Can Ga-67-Dowex 50 W be used as an alternative compound for colonic transit evaluation?**
Savas O., Cabuk M., Cevher E., Aydemir S., Ocak M., Sen F., Aksoy N. B., Atik D. Y.
20th Annual Congress of the European-Association-of-Nuclear-Medicine, Copenhagen, Denmark, 01 January 2007

LXII. **Metilen mavisi ile stabilize edilmiş HMPAO kitinin bölünmüş dozlardaki işaretleme verimliliği ve kararlılık süresinin kromatografik yolla incelenmesi**
ADAY H. S., OCAK DEMİRCİ E. M., ADAY A., TÜRKMEN C., KABASAKAL L., ÜNAL S. N.
7th International Congress of Nuclear Oncology & 18th National Congress of the Turkish Society of Nuclear Medicine, Antalya, Turkey, 13 - 17 May 2006, vol.15, no.1

Other Publications

I. **Appearance of intracranial meningioma in FDG and 68Ga-DOTATOC PET/CT.**
Sabire Y., OCAK ., asa s., Gülşen F., Halaç M., KABASAKAL L.
Other, pp.60-61, 2013

II. **Intraoperative localization of recurrent medullary carcinoma of the thyroid using Tc-99m HYNIC-TATE and a surgical gamma probe.**
Aliev A., OCAK E. M., Kabasakal L., et.al ..
Other, pp.831-3, 2011

III. **Impurity in (68)Ga-peptide preparation using processed generator eluate.**
Petrik M., OCAK E. M., Rupprich M., Decristoforo C.
Technical Report, pp.495, 2010

Supported Projects

OCAK DEMİRCİ E. M., TUBITAK Project, Küçük molekül prostat spesifik membran antijen inhibitörlerinin (PSMAi) işaretlenmesi, 2017 - Continues

OCAK DEMİRCİ E. M., TUBITAK Project, PET YÖNTEMİ İLE TÜMÖR GÖRÜNTÜLENMESİ İÇİN GALYUM-68 (GA-68) İ? ARETLİ NANOBOYUTLU TÜMÖRE HEDEFLENDİRİLMİ? LİPOZOMAL İLAÇ TA?IYICI SİSTEMLERİN GELİ?TİRİLMESİ, 2015 - Continues

ÇAĞLAR ANDAÇ S., PEHLİVANOĞLU H., OCAK DEMİRCİ E. M., Project Supported by Higher Education Institutions, 68Ga PSMA 11 Üretimine ve Radyokimyasal Saflık Analizine Tasarımla Kalite QbD Prensiplerine Göre Kalite Uygulaması, 2019 - 2019

ARAMAN A. O., OCAK DEMİRCİ E. M., Project Supported by Higher Education Institutions, GMP koşullarda Majistral Radyofarmasötik Üretimi, 2014 - 2019

KABASAKAL L., OCAK DEMİRCİ E. M., AKKUŞ B., ARAMAN A. O., Project Supported by Higher Education Institutions, Tc-

99m-oktreotate sintigrafisi ile Lu-177-oktreotate radyasyon dozunun belirlenmesi, 2013 - 2017
SÖNMEZOĞLU K., ARAMAN A. O., OCAK DEMİRCİ E. M., Project Supported by Higher Education Institutions, F-18 FLUOROCHOLINE ÜRETİMİ VE POZİTRON EMİSYON TOMOGRAFİSİ (PET) GÖRÜNTÜLEMEDE KULLANILARAK MUHTELİF MALİGNİTELERİN EVRELENMESİNDEKİ ETKİNLİĞİNİN ARAŞTIRILMASI, 2012 - 2014
ERGİNER Y., OCAK DEMİRCİ E. M., TUBITAK Project, Radyonüklid tedavi için Lutesyum 177 (Lu-177) işaretli radyopeptidlerin kararlılık çalışmalarının standardizasyonu, 2009 - 2011
KABASAKAL L., ARAMAN A. O., OCAK DEMİRCİ E. M., Project Supported by Higher Education Institutions, Ga-68 işaretli somatostatin peptidleri ile yapılan PET/BT sintigrafisinin somatostatin reseptörü içeren lezyonların tanısındaki değeri, 2009 - 2011

Memberships / Tasks in Scientific Organizations

European Society for Molecular Imaging (ESMI), Member, 2014 - Continues
Türkiye Nükleer Tıp Derneği, Member, 2004 - Continues
European Association of Nuclear Medicine (EANM), Radiopharmacy Committe, Board Member, 2014 - 2021, Austria

Scientific Refereeing

Istanbul Journal of Pharmacy, National Scientific Refreed Journal, August 2020
TUBITAK Project, 1501 - Industry R & D Projects Support Program, ELİXİR İLAÇ ARAŞTIRMA VE GELİŞTİRME ANONİM ŞİRKETİ (ANKARA), Turkey, July 2020
TUBITAK Project, 1501 - Industry R & D Projects Support Program, ECZACIBAŞI MONROL NÜKLEER ÜRÜNLER SAN. VE TİC. A.Ş. (KOCAELİ), Turkey, July 2020
Cancer Biotherapy and Radiopharmaceuticals , SCI Journal, July 2016
TUBITAK Project, March 2016
TUBITAK Project, March 2016
TUBITAK Project, December 2015
TUBITAK Project, September 2015
Pharmaceutical Development and Technology, SCI Journal, April 2015
Applied Radiation and Isotopes, SCI Journal, January 2015
Nuclear Medicine and Biology, SCI Journal, August 2014
PLoS ONE, SCI Journal, August 2014
Nuclear Medicine and Biology, SCI Journal, August 2014
TUBITAK Project, July 2014
Turkish Journal Biochemistry, Other Indexed Journal, November 2012

Scientific Consultations

TUBİTAK, Other, Istanbul University, Faculty Of Pharmacy , Department of Pharmaceutical Technology, Turkey, 2015 - Continues
T.C. Sağlık Bakanlığı Türkiye İlaç ve Tıbbi Cihaz Kurumu, Radyofarmasi Komisyonu, Scientific Consultancy, Istanbul University, Faculty Of Pharmacy , Department of Pharmaceutical Technology, Turkey, 2011 - 2015

Scientific Research / Working Group Memberships

Radyofarmasi Çekirdek Komisyon Üyeliği, Türkiye NükleerTıp Derneği, Turkey, http://www.tsnm.org/radyofarmasi, 2015 - Continues
Radiopharmacy Committee, European Association Of Nuclear Medicine, Austria,

http://www.eanm.org/committees/radiopharmacy/index.php?navId=225, 2014 - Continues

Metrics

Publication: 157
Citation (WoS): 1156
Citation (Scopus): 1151
H-Index (WoS): 18
H-Index (Scopus): 18

Congress and Symposium Activities

32nd Annual Congress of the European-Association-of-Nuclear-Medicine (EANM!19), Attendee, Barcelona, Spain, 2019
31st Annual Congress of the European-Association-of-Nuclear-Medicine (EANM'18), Attendee, Düsseldorf, Germany, 2018
30th Annual Congress of the European-Association-of-Nuclear-Medicine (EANM'17), Attendee, Vienna, Austria, 2017
SNMMI 2016 Annual Meeting, Attendee, California, United States Of America, 2016
28th Annual Congress of the European-Association-of-Nuclear-Medicine (EANM'15), Attendee, Hamburg, Germany, 2015
Annual Congress of the European Association of Nuclear Medicine, EANM'14, Attendee, Göteborg, Sweden, 2014
9. Tiroler Nuklearmedizinkongress, Attendee, Innsbruck, Austria, 2014
SNMMI's 60th Annual Meeting, Attendee, Vancouver, Canada, 2013
SNM's 59th Annual Meeting, Attendee, Miami, United States Of America, 2012
Nöroendokrin Tümör Tanı ve Tedavisinde Güncel Gelişmeler Sempozyumu, Attendee, Edirne, Turkey, 2011
23. Ulusal Nükleer Tıp Kongresi, Attendee, İzmir, Turkey, 2011
COST BM0607 Working Group and MC meeting, Attendee, Innsbruck, Austria, 2011
23 rd Annual Congress of the European Association of Nuclear Medicine-EANM'10, Attendee, Viyena, Austria, 2010
15th European Symposium on Radiopharmacy and Radiopharmaceuticals, Attendee, Edinburg, United Kingdom, 2010
9th International Nuclear Oncology Congress & 22. Ulusal Nükleer Tıp Kongresi, Attendee, Antalya, Turkey, 2010
22nd Annual Congress of the European Association of Nuclear Medicine-EANM'09, Attendee, Barselona, Spain, 2009
21. Ulusal Nükleer Tıp Kongresi, Attendee, Antalya, Turkey, 2009
Kontrollü Salım Sistemleri 6. Sempozyumu, Attendee, Istanbul, Turkey, 2009
1st Tarcc International Workshop on Targeted Radionuclide Therapy, Attendee, Nantes, France, 2009
7. Jahrestagung Der Gesellschaft für Nuclearmedizin, Attendee, Salzburg, Austria, 2009
21th Annual Congress of the European Association of Nuclear Medicine-EANM'08, Attendee, Münih, Germany, 2008
19th International Research Group in Immuno-Scintigraphy and Therapy Meeting, Attendee, Krakow, Poland, 2008
Work Group Meeting of COST BM0607 action, Attendee, Krakow, Poland, 2008
14th European Symposium on Radiopharmacy and Radiopharmaceuticals, Attendee, Üsküp, Macedonia, 2008
8 th International Nuclear Oncology Congress & 20. Ulusal Nükleer Tıp Kongresi, Attendee, İstanbul, Turkey, 2008
Zamanı Etkin Kullanabilme Becerimiz ve Yapımız, Attendee, İstanbul, Turkey, 2007
7th International Congress of Nuclear Oncology &18th National Congress of the Turkish Society of Nuclear Medicine, Attendee, Antalya, Turkey, 2006
Eczacılık Teknolojisi Seminer Günleri II, Attendee, İzmir, Turkey, 2006
8. International Symposium on Trends in Radiopharmaceuticals (ISTR-2005), Attendee, Viyana, Austria, 2005
Kontrollü Salım Sistemleri 4. Sempozyumu, Attendee, İstanbul, Turkey, 2005
4th International Postgraduate Research Symposium on Pharmaceutics, Attendee, İstanbul, Turkey, 2004
International Congress of Radiopharmacy and Radiopharmaceutical Chemistry& 1st Turkish Congress of Radiopharmacy, Attendee, İstanbul, Turkey, 2004
Kontrollü Salım Sistemleri 3. Sempozyumu, Attendee, İstanbul, Turkey, 2003

Scholarships

Scholarship of COST STSM, European Commission, 2011 - Continues
Innsbruck, Avusturya'da doktora araştırması desteği, Foundation, 2007 - Continues

Awards

OCAK DEMİRCİ E. M., Prf.Dr.Suphi Artunkal Ödülü, Turkish Society of Nuclear Medicine, April 2017
OCAK DEMİRCİ E. M., Genç Araştırmacı Ödülü, Turkish Society of Nuclear Medicine, April 2016
OCAK DEMİRCİ E. M., Prof.Dr.Suphi Artunkal Ödülü, Turkish Society of Nuclear Medicine, April 2016
OCAK DEMİRCİ E. M., 40.yıl Arastırma Ödülü, Turkish Society of Nuclear Medicine, April 2015
OCAK DEMİRCİ E. M., Prof.Dr.Suphi Artunkal Ödülü, Turkish Society of Nuclear Medicine, April 2013
OCAK DEMİRCİ E. M., Poster Birincilik Ödülü, Turkish Society of Nuclear Medicine, November 2011
OCAK DEMİRCİ E. M., Award of Prof.Dr.Suphi Artunkal, 9 th International Congress of Nuclear Oncology and 22 th National Congress of the Turkish Society of Nuclear Medicine, April 2010
OCAK DEMİRCİ E. M., Young Investigator Award, 8 th International Congress of Nuclear Oncology and 20 th National Congress of the Turkish Society of Nuclear Medicine, April 2008
OCAK DEMİRCİ E. M., Best Poster Awards, 9 th Congress of the World Federation of Nuclear Medicine and Biology, October 2006